Drug resistance in antiviral therapy

Clinics in Liver Disease

Volumn 14, Issue 3, 2010, Pages 439-459

  Locarnini, Stephen ^a   Bowden, Scott ^a  

^a VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

Author keywords

Antiviral resistance; Hepatitis B virus; Multidrug resistance; Nucleoside analog; Nucleotide analog; Reverse transcriptase

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ANTIVIRUS AGENT; ENTECAVIR; LAMIVUDINE; TELBIVUDINE; TENOFOVIR; VIRUS DNA; NUCLEOSIDE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIVIRAL ACTIVITY; CROSS RESISTANCE; DISEASE SEVERITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; NONHUMAN; REVIEW; TREATMENT OUTCOME; VIRUS GENOME; VIRUS LOAD; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS TRANSMISSION; CHEMISTRY; DRUG EFFECTS; HEPATITIS B, CHRONIC; LIVER; METABOLISM; MULTIDRUG RESISTANCE; MUTATION; PHYSIOLOGY; VIRUS GENE;

ANTIVIRAL AGENTS; DRUG RESISTANCE, MULTIPLE, VIRAL; GENES, VIRAL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LIVER; MUTATION; NUCLEOSIDES; REVERSE TRANSCRIPTASE INHIBITORS; VIRUS REPLICATION;

EID: 77954636329     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2010.05.004     Document Type: Review

References (88)

1. Locarnini S. Molecular virology and the development of resistant mutants: implications for therapy. Semin Liver Dis 2005, 25(Suppl 1):9.
2. Chisari F.V., Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995, 13(Suppl 1):29.
3. Chen C.J., Yang H.I., Su J., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006, 295:65.
4. Iloeje U.H., Yang H.I., Su J., et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006, 130:678.
5. Shaw T., Locarnini S. Entecavir for the treatment of chronic hepatitis B. Expert Rev Anti Infect Ther 2004, 2:853.
6. Domingo E. Quasispecies and the development of new antiviral strategies. Prog Drug Res 2003, 60:133.
7. Locarnini S., Hatzakis A., Heathcote J., et al. Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther 2004, 9:679.
8. Lok A.S., Zoulim F., Locarnini S., et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 2007, 46:254.
9. Pawlotsky J.M., Dusheiko G., Hatzakis A., et al. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology 2008, 134:405.
10. Lai C.L., Dienstag J., Schiff E., et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003, 36:687.
11. Nafa S., Ahmed S., Tavan D., et al. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology 2000, 32:1078.
12. Zoulim F., Poynard T., Degos F., et al. A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine. J Viral Hepat 2006, 13:278.
13. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006, 131:1743.
14. Lai C.L., Gane E., Liaw Y.F., et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007, 357:2576.
15. Yuen M.F., Sablon E., Hui C.K., et al. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001, 34:785.
16. Lewin S.R., Ribeiro R.M., Walters T., et al. Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed. Hepatology 2001, 34:1012.
17. Nowak M.A., Bonhoeffer S., Hill A.M., et al. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci U S A 1996, 93:4398.
18. Zhou Y., Holmes E.C. Bayesian estimates of the evolutionary rate and age of hepatitis B virus. J Mol Evol 2007, 65:197.
19. Duffy S., Shackelton L.A., Holmes E.C. Rates of evolutionary change in viruses: patterns and determinants. Nat Rev Genet 2008, 9:267.
20. Girones R., Miller R.H. Mutation rate of the hepadnavirus genome. Virology 1989, 170:595.
21. Richman D.D. The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B. Hepatology 2000, 32:866.
22. Richman D.D. The implications of drug resistance for strategies of combination antiviral chemotherapy. Antiviral Res 1996, 29:31.
23. Villet S., Billioud G., Pichoud C., et al. In vitro characterization of viral fitness of therapy-resistant hepatitis B variants. Gastroenterology 2009, 136:168.
24. Zhang Y.Y., Summers J. Enrichment of a precore-minus mutant of duck hepatitis B virus in experimental mixed infections. J Virol 1999, 73:3616.
25. Zhang Y.Y., Summers J. Low dynamic state of viral competition in a chronic avian hepadnavirus infection. J Virol 2000, 74:5257.
26. Seeger C., Mason W.S. Hepatitis B virus biology. Microbiol Mol Biol Rev 2000, 64:51.
27. Mason W.S., Jilbert A.R., Summers J. Clonal expansion of hepatocytes during chronic woodchuck hepatitis virus infection. Proc Natl Acad Sci U S A 2005, 102:1139.
28. Mason W.S., Litwin S., Xu C., et al. Hepatocyte turnover in transient and chronic hepadnavirus infections. J Viral Hepat 2007, 14(Suppl 1):22.
29. Thibault V., Aubron-Olivier C., Agut H., et al. Primary infection with a lamivudine-resistant hepatitis B virus. AIDS 2002, 16:131.
30. Niesters H.G., De Man R.A., Pas S.D., et al. Identification of a new variant in the YMDD motif of the hepatitis B virus polymerase gene selected during lamivudine therapy. J Med Microbiol 2002, 51:695.
31. Lok A.S., Zoulim F., Locarnini S., et al. Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay. J Clin Microbiol 2002, 40:3729.
32. Tenney D.J., Rose R.E., Baldick C.J., et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009, 49:1503.
33. Shaw T., Locarnini S.A. Preclinical aspects of lamivudine and famciclovir against hepatitis B virus. J Viral Hepat 1999, 6:89.
34. Locarnini S., Mason W.S. Cellular and virological mechanisms of HBV drug resistance. J Hepatol 2006, 44:422.
35. Delaney W.E., Locarnini S., Shaw T. Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation. Antivir Chem Chemother 2001, 12:1.
36. Shaw T., Bartholomeusz A., Locarnini S. HBV drug resistance: mechanisms, detection and interpretation. J Hepatol 2006, 44:593.
37. Yeh C.T., Chien R.N., Chu C.M., et al. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology 2000, 31:1318.
38. Ogata N., Fujii K., Takigawa S., et al. Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in japanese patients with chronic hepatitis B. J Med Virol 1999, 59:270.
39. Delaney W.E., Yang H., Westland C.E., et al. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol 2003, 77:11833.
40. Bartholomeusz A., Locarnini S., Ayres A., et al. Mechanistic basis for hepatitis B virus resistance to acyclic nucleoside phosphonate analogues, adefovir and tenofovir. Hepatology 2005, 42(Suppl 1):594A.
41. Fung S.K., Andreone P., Han S.H., et al. Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol 2005, 43:937.
42. Tenney D.J., Levine S.M., Rose R.E., et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother 2004, 48:3498.
43. Bartholomeusz A., Tehan B.G., Chalmers D.K. Comparisons of the HBV and HIV polymerase, and antiviral resistance mutations. Antivir Ther 2004, 9:149.
44. Angus P., Vaughan R., Xiong S., et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003, 125:292.
45. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005, 352:2673.
46. Bartholomeusz A., Locarnini S., Ayres A., et al. Molecular modelling of hepatitis b virus polymerase and adefovir resistance identifies three clusters of mutations. Hepatology 2004, 40(Suppl 1):246A.
47. Schildgen O., Sirma H., Funk A., et al. Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med 2006, 354:1807.
48. Chang T.T., Lai C.L. Hepatitis B virus with primary resistance to adefovir. N Engl J Med 2006, 355:322.
49. Levine S., Hernandez D., Yamanaka G., et al. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob Agents Chemother 2002, 46:2525.
50. Suzuki F., Akuta N., Suzuki Y., et al. Selection of a virus strain resistant to entecavir in a nucleoside-naive patient with hepatitis B of genotype H. J Clin Virol 2007, 39:149.
51. Colonno R.J., Rose R., Baldick C.J., et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 2006, 44:1656.
52. Warner N., Locarnini S., Colledge D., et al. Molecular modelling of entecavir resistant mutations in the hepatitis B virus polymerase selected during therapy. Hepatology 2004, 40:245A.
53. Yuen L., Bartholomeusz A., Ayres A., et al. Multidrug resistance and cross-resistance pathways in HBV as a consequence of treatment failure. Hepatology 2007, 46(4 Suppl 1):659A. [abstract #949].
54. Van Bommel F., Trojan J., Wasmuth H., et al. Efficacy of tenofovir DF for the treatment of adefovir resistance. Hepatology 2007, 46(Suppl 1):664A. [abstract 960].
55. Warner N., Locarnini S. The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology 2008, 48:88.
56. Martinez-Cajas J.L., Wainberg M.A. Antiretroviral therapy: optimal sequencing of therapy to avoid resistance. Drugs 2008, 68:43.
57. Clavel F., Hance A.J. HIV drug resistance. N Engl J Med 2004, 350:1023.
58. EASL Clinical Practice Guidelines Management of chronic hepatitis B. Hepatology 2009, 50:227.
59. Villet S., Ollivet A., Pichoud C., et al. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J Hepatol 2007, 46:531.
60. Yim H.J., Hussain M., Liu Y., et al. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 2006, 44:703.
61. Brunelle M.N., Jacquard A.C., Pichoud C., et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 2005, 41:1391.
62. Villet S., Pichoud C., Villeneuve J.P., et al. Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology 2006, 131:1253.
63. Villet S., Pichoud C., Billioud G., et al. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol 2008, 48:747.
64. Lok A.S., Lai C.L., Leung N., et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003, 125:1714.
65. Dienstag J.L., Goldin R.D., Heathcote E.J., et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003, 124:105.
66. Liaw Y.F., Sung J.J., Chow W.C., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004, 351:1521.
67. Torresi J., Earnest-Silveira L., Deliyannis G., et al. Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology 2002, 293:305.
68. Lai M.W., Huang S.F., Hsu C.W., et al. Identification of nonsense mutations in hepatitis B virus S gene in patients with hepatocellular carcinoma developed after lamivudine therapy. Antivir Ther 2009, 14:249.
69. Kamili S., Sozzi V., Thompson G., et al. Efficacy of hepatitis B vaccine against antiviral drug-resistant hepatitis B virus mutants in the chimpanzee model. Hepatology 2009, 49:1483.
70. Besisik F., Karaca C., Akyuz F., et al. Occult HBV infection and YMDD variants in hemodialysis patients with chronic HCV infection. J Hepatol 2003, 38:506.
71. Kobayashi S., Ide T., Sata M. Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers. J Hepatol 2001, 34:584.
72. Hayashi K., Katano Y., Ishigami M., et al. Prevalence and clinical characterization of patients with acute hepatitis B induced by lamivudine-resistantstrains. J Gastroenterol Hepatol 2010, 25:745-749.
73. Zoulim F., Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009, 137:1593.
74. Clements C., Coghlan B., Creati M., et al. Global control of hepatitis B infection: does the potential for antigenic change of the virus in the face of antiviral treatment affect the global hepatitis B immunization programme?. Bull World Health Organ 2009, 88(1):1-80.
75. Bowden S., Shaw T., Hepatitis B. The case for combination therapy. Curr Opin Investig Drugs 2009, 10:795.
76. Sung J.J., Lai J.Y., Zeuzem S., et al. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol 2008, 48:728.
77. Lau G.K., Piratvisuth T., Luo K.X., et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005, 352:2682.
78. Marcellin P., Lau G.K., Bonino F., et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004, 351:1206.
79. Lampertico P., Vigano M., Manenti E., et al. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007, 133:1445.
80. Zoulim F., Perrillo R., Hepatitis B. Reflections on the current approach to antiviral therapy. J Hepatol 2008, 48(Suppl 1):S2.
81. Fournier C., Zoulim F. Antiviral therapy of chronic hepatitis B: prevention of drug resistance. Clin Liver Dis 2007, 11:869.
82. Leigh Brown A.J., Frost S.D., Mathews W.C., et al. Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. J Infect Dis 2003, 187:683.
83. Little S.J., Holte S., Routy J.P., et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002, 347:385.
84. Hirsch M.S., Brun-Vezinet F., Clotet B., et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 2003, 37:113.
85. Little S.J., Frost S.D., Wong J.K., et al. Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol 2008, 82:5510.
86. Yuen L.K., Ayres A., Littlejohn M., et al. SeqHepB: a sequence analysis program and relational database system for chronic hepatitis B. Antiviral Res 2007, 75:64.
87. Gauthier J., Bourne E.J., Lutz M.W., et al. Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine. J Infect Dis 1999, 180:1757.
88. Shaw T., Locarnini S. Combination chemotherapy for hepatitis B virus: the path forward?. Drugs 2000, 60:517.